Oral Cavity Squamous Cell Carcinoma and the Clinically N0 Neck: The Past, Present, and Future of Sentinel Lymph Node Biopsy
Identifieur interne : 002792 ( Pmc/Corpus ); précédent : 002791; suivant : 002793Oral Cavity Squamous Cell Carcinoma and the Clinically N0 Neck: The Past, Present, and Future of Sentinel Lymph Node Biopsy
Auteurs : Andrew Coughlin ; Vicente A. RestoSource :
- Current oncology reports [ 1523-3790 ] ; 2010.
Abstract
Oral cavity squamous cell carcinoma (OCSCC) has a yearly incidence of 274,000 patients. Twenty percent to 30% of patients will harbor occult regional metastases, an important feature that correlates with worse outcomes. Supraomohyoid neck dissection (SND) is the gold standard treatment, but because of recent successes of sentinel lymph node (SLN) biopsy in the management of breast cancer and melanoma, many have begun evaluating its use in head and neck mucosal cancers. SLN biopsy offers patients decreased morbidity compared with SND, and has shown reproducibly low false-negative rates, high-negative predictive values, and high sensitivities. Limitations with floor-of-mouth primaries and delayed secondary SNDs have been described, but a new agent designed to address these shortcomings, Lymphoseek (Neoprobe Corp.; Dublin, OH), is currently under investigation. This article reviews the current literature on SLN biopsy and introduces a phase 3 study evaluating the efficacy of Lymphoseek in SLN biopsy of OCSCCs.
Url:
DOI: 10.1007/s11912-010-0090-7
PubMed: 20425598
PubMed Central: 2862587
Links to Exploration step
PMC:2862587Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Oral Cavity Squamous Cell Carcinoma and the Clinically N0 Neck: The Past, Present, and Future of Sentinel Lymph Node Biopsy</title><author><name sortKey="Coughlin, Andrew" sort="Coughlin, Andrew" uniqKey="Coughlin A" first="Andrew" last="Coughlin">Andrew Coughlin</name></author><author><name sortKey="Resto, Vicente A" sort="Resto, Vicente A" uniqKey="Resto V" first="Vicente A." last="Resto">Vicente A. Resto</name></author></titleStmt><publicationStmt><idno type="wicri:source">PMC</idno><idno type="pmid">20425598</idno><idno type="pmc">2862587</idno><idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2862587</idno><idno type="RBID">PMC:2862587</idno><idno type="doi">10.1007/s11912-010-0090-7</idno><date when="2010">2010</date><idno type="wicri:Area/Pmc/Corpus">002792</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">002792</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Oral Cavity Squamous Cell Carcinoma and the Clinically N0 Neck: The Past, Present, and Future of Sentinel Lymph Node Biopsy</title><author><name sortKey="Coughlin, Andrew" sort="Coughlin, Andrew" uniqKey="Coughlin A" first="Andrew" last="Coughlin">Andrew Coughlin</name></author><author><name sortKey="Resto, Vicente A" sort="Resto, Vicente A" uniqKey="Resto V" first="Vicente A." last="Resto">Vicente A. Resto</name></author></analytic><series><title level="j">Current oncology reports</title><idno type="ISSN">1523-3790</idno><idno type="eISSN">1534-6269</idno><imprint><date when="2010">2010</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><p id="P1">Oral cavity squamous cell carcinoma (OCSCC) has a yearly incidence of 274,000 patients. Twenty percent to 30% of patients will harbor occult regional metastases, an important feature that correlates with worse outcomes. Supraomohyoid neck dissection (SND) is the gold standard treatment, but because of recent successes of sentinel lymph node (SLN) biopsy in the management of breast cancer and melanoma, many have begun evaluating its use in head and neck mucosal cancers. SLN biopsy offers patients decreased morbidity compared with SND, and has shown reproducibly low false-negative rates, high-negative predictive values, and high sensitivities. Limitations with floor-of-mouth primaries and delayed secondary SNDs have been described, but a new agent designed to address these shortcomings, Lymphoseek (Neoprobe Corp.; Dublin, OH), is currently under investigation. This article reviews the current literature on SLN biopsy and introduces a phase 3 study evaluating the efficacy of Lymphoseek in SLN biopsy of OCSCCs.</p></div></front></TEI><pmc article-type="research-article" xml:lang="EN"><pmc-comment>The publisher of this article does not allow downloading of the full text in XML form.</pmc-comment>
<pmc-dir>properties manuscript</pmc-dir>
<front><journal-meta><journal-id journal-id-type="nlm-journal-id">100888967</journal-id><journal-id journal-id-type="pubmed-jr-id">21927</journal-id><journal-id journal-id-type="nlm-ta">Curr Oncol Rep</journal-id><journal-title>Current oncology reports</journal-title><issn pub-type="ppub">1523-3790</issn><issn pub-type="epub">1534-6269</issn></journal-meta><article-meta><article-id pub-id-type="pmid">20425598</article-id><article-id pub-id-type="pmc">2862587</article-id><article-id pub-id-type="doi">10.1007/s11912-010-0090-7</article-id><article-id pub-id-type="manuscript">NIHMS194964</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Oral Cavity Squamous Cell Carcinoma and the Clinically N0 Neck: The Past, Present, and Future of Sentinel Lymph Node Biopsy</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Coughlin</surname><given-names>Andrew</given-names></name><email>amcoughl@utmb.edu</email></contrib><contrib contrib-type="author"><name><surname>Resto</surname><given-names>Vicente A.</given-names></name><email>varesto@utmb.edu</email></contrib><aff id="A1">Department of Otolaryngology, Head and Neck Surgery, University of Texas Medical Branch, 301 University Boulevard, Galveston, TX 77555, USA</aff></contrib-group><pub-date pub-type="nihms-submitted"><day>16</day><month>4</month><year>2010</year></pub-date><pub-date pub-type="ppub"><month>3</month><year>2010</year></pub-date><pub-date pub-type="pmc-release"><day>1</day><month>3</month><year>2011</year></pub-date><volume>12</volume><issue>2</issue><fpage>129</fpage><lpage>135</lpage><permissions><copyright-statement>© Springer Science+Business Media, LLC 2010</copyright-statement><copyright-year>2010</copyright-year></permissions><abstract><p id="P1">Oral cavity squamous cell carcinoma (OCSCC) has a yearly incidence of 274,000 patients. Twenty percent to 30% of patients will harbor occult regional metastases, an important feature that correlates with worse outcomes. Supraomohyoid neck dissection (SND) is the gold standard treatment, but because of recent successes of sentinel lymph node (SLN) biopsy in the management of breast cancer and melanoma, many have begun evaluating its use in head and neck mucosal cancers. SLN biopsy offers patients decreased morbidity compared with SND, and has shown reproducibly low false-negative rates, high-negative predictive values, and high sensitivities. Limitations with floor-of-mouth primaries and delayed secondary SNDs have been described, but a new agent designed to address these shortcomings, Lymphoseek (Neoprobe Corp.; Dublin, OH), is currently under investigation. This article reviews the current literature on SLN biopsy and introduces a phase 3 study evaluating the efficacy of Lymphoseek in SLN biopsy of OCSCCs.</p></abstract><kwd-group><kwd>Sentinel lymph node mapping</kwd><kwd>Oral cavity cancer</kwd><kwd>Staging</kwd><kwd>Lymphoscintigraphy</kwd><kwd>Occult lymph node metastases</kwd></kwd-group><contract-num rid="CA1">K08 CA132988-01A2
||CA</contract-num><contract-sponsor id="CA1">National Cancer Institute : NCI</contract-sponsor></article-meta></front></pmc></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/Pmc/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002792 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Pmc/Corpus/biblio.hfd -nk 002792 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= LymphedemaV1
|flux= Pmc
|étape= Corpus
|type= RBID
|clé= PMC:2862587
|texte= Oral Cavity Squamous Cell Carcinoma and the Clinically N0 Neck: The Past, Present, and Future of Sentinel Lymph Node Biopsy
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Pmc/Corpus/RBID.i -Sk "pubmed:20425598" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Pmc/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a LymphedemaV1
| This area was generated with Dilib version V0.6.31. |  |